Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Forte Biosciences, Inc. (FBRX) director Steven Kornfeld reported that, in connection with a merger in which Forte became a wholly owned subsidiary of argenx BV, all of his reported Forte equity was disposed of on August 27, 2026. Common shares that were tendered were exchanged for $77.00 per share in cash, net to the seller, subject to withholding tax.
Unexercised stock options with exercise prices below $77.00 were canceled and converted into the right to receive a lump-sum cash payment equal to the excess of the $77.00 Merger Consideration over the option’s exercise price, multiplied by the number of shares subject to each option. Options with exercise prices at or above $77.00 were canceled with no consideration. All reported restricted stock units were canceled and converted into the right to receive a cash payment equal to $77.00 multiplied by the number of underlying shares.
Forte Biosciences, Inc. (FBRX) director Scott C. Brun reported the cancellation and disposition to the issuer of stock options and restricted stock units in connection with a merger. On August 27, 2026, unexercised options with per share exercise prices below the $77.00 merger consideration and outstanding RSUs were canceled and converted into rights to receive lump-sum cash payments, while options with exercise prices at or above $77.00 were canceled for no consideration.
Forte Biosciences, Inc. (FBRX) director David W. Gryska reported dispositions of common stock and equity awards in connection with the company’s merger with argenx BV. He tendered 5,940 shares of common stock into a tender offer at $77.00 per share in cash. Unexercised stock options with exercise prices below $77.00 covering 36,000 shares in total and 18,353 restricted stock units were canceled and converted into lump-sum cash rights based on the $77.00 Merger Consideration, subject to withholding taxes, while certain higher-priced options were canceled with no consideration. Following the merger, Forte Biosciences became a wholly owned subsidiary of argenx BV.
Forte Biosciences, Inc. (FBRX) director Richard G. Vincent reported the disposition of equity awards in connection with a merger under which Forte becomes a wholly owned subsidiary of argenx BV. On 2026-08-27, unexercised stock options for 2,000 shares at a $7.07 exercise price and 31,000 shares at a $7.54 exercise price, and 18,353 restricted stock units, were canceled. Under the Merger Agreement, in-the-money options and RSUs are converted into a right to receive cash based on $77.00 per share, while options with exercise prices at or above that amount are canceled with no consideration.